Brokerage : Hana Securities
Analyst : Seona Kim (RA: Changkeun Yoo)
Investment Rating : BUY (Maintained)
Target Price : KRW 2,050,000 (Maintained)
Core Momentum : Acquisition of the US Rockville site finalized, driving scheduled H2 revenue recognition and an estimated ~5% upward revision in annual guidance alongside enhanced tariff risk resilience.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY (Maintained) / Target Price (12M) KRW 2,050,000 (Maintained) (Derived applying a target EV/EBITDA multiple of 34x—reflecting a 2x premium over peers based on superior profitability—to 2027E EBITDA discounted at WACC 8.7%; closing price as of April 1, 2026: KRW 1,572,000)
- Market Data: KOSPI Index 5,478.70pt / Market Cap KRW 72.77 Trillion / Shares Outstanding 46,291,000 / Foreign Ownership 12.73% / Major Shareholders: Samsung C&T and 5 affiliates 74.31%, National Pension Service 6.68%
- Annual Financial Forecast (Hana Securities Estimates):
- 2026F: Revenue KRW 5.55 Trillion, Operating Profit KRW 2.50 Trillion, Pre-tax Profit KRW 2.59 Trillion, Net Profit KRW 1.97 Trillion, EPS KRW 42,482, BPS KRW 226,489, PER 37.00x, PBR 6.94x, ROE 23.42%, EV/EBITDA 25.61x
- 2027F: Revenue KRW 6.33 Trillion, Operating Profit KRW 2.89 Trillion, Pre-tax Profit KRW 3.01 Trillion, Net Profit KRW 2.29 Trillion, EPS KRW 49,440, BPS KRW 275,851, PER 31.80x, PBR 5.70x, ROE 21.75%, EV/EBITDA 22.13x
🚀 2. [Market Opportunities & Business Outlook]
- Q1 2026 Earnings Preview:
- Consolidated revenue is projected at KRW 1.26 Trillion (+26.5% YoY) and operating profit at KRW 558.7 Billion (+29.9% YoY, OPM 44.2%).
- Favorable FX trends persist with Q1 average trading rates at 1,465 KRW/USD, comfortably supporting the baseline annual revenue growth guidance of 15%–20%.
- Scheduled maintenance for Plant 1 (30,000L capacity) in Q4 will impact Q1 2027 revenues, presenting no material disruption to full-year 2026 targets.
- Rockville Facility Integration & Guidance Upside:
- The acquisition of the US Rockville site was finalized in late March at approximately USD 350 Million (~KRW 525.0 Billion, adjusted upward from USD 280 Million due to additional asset/inventory transfers).
- The 60,000-liter facility (equivalent to twice the size of Songdo Plant 1) will begin revenue recognition in Q3 based on Q2 production. It is projected to contribute over KRW 250 Billion in annual revenue (~4.2% of 2026 full-year estimates), positioning the company for an estimated ~5% upward revision to annual guidance upon Q1 or Q2 earnings announcements.
- Tariff Resilience & Medium-Term Expansion Roadmap:
- Securing US manufacturing operations establishes strong resilience against global trade and pharmaceutical tariff uncertainties.
- Directional decisions regarding capital allocation—whether prioritizing Songdo Plant 6 groundbreaking or further expanding the Rockville footprint—will serve as key operational catalysts for subsequent valuation upgrades.
📝 Editor’s Comment (Perspective)
The analyst views Samsung Biologics as a premier global CDMO maintaining industry-leading profitability (mid-40% OPM vs. peer Lonza’s ~23%) while establishing geographical resilience against US tariff risks via the finalized Rockville acquisition. The overarching perspective prioritizes the qualitative benefits of expanding into the US market, the potential ~5% upward guidance revision from Q3 Rockville revenue consolidation, and subsequent CAPEX expansion milestones over quarterly preview variances.
To verify whether this investment thesis progresses as expected, investors should primarily monitor the actual quarterly revenue recognition and margin profile of the Rockville site starting in Q3, official upward revisions to full-year corporate revenue guidance, and formal announcements regarding the timeline for Songdo Plant 6 groundbreaking or US capacity additions. These developments can be verified through future quarterly earnings releases, official company IR presentations, and regulatory filings on DART/KRX.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
